NeoStem, an international biopharmaceutical company, has adult stem cell operations in the U.S., with cell therapy production facilities in New Jersey and California through its acquisition of Progenitor Cell Therapy, LLC. NeoStem also has a network of adult stem cell therapeutic providers in China, and owns majority interest in Suzhou Erye Pharmaceuticals, a profitable Chinese generic pharmaceutical production company in Suzhou Jiangsu, west of Shanghai. NeoStem has licensed various cellular therapy technologies, and holds the exclusive worldwide rights to a wound healing technology in addition to VSELTM (very small embryonic-like) stem cell technology, involving adult stem cells that have been shown to have several physical characteristics generally found in embryonic stem cells.
Progenitor Cell Therapy, acquired by NeoStem in January of 2011, represents over 100 years of collective experience in the business and science of cell therapy and development. PCT has served over 100 clients from around the world, and has experience with over 20 different cell-based therapeutics. PCT has performed over 30,000 cell therapy procedures, processed and stored over 18,000 cell therapy products, and has arranged the logistics and transportation for over 14,000 cell therapy products for clinical use by over 5,000 patients.
The cornerstone of NeoStem’s China operations is its 51% interest in Suzhou Erye, a well-established vertically-integrated pharmaceutical company focused primarily on the manufacturing and sale of antibiotics, with seven products in its current pipeline. Erye’s new product facility will significantly increase its capacity, expected to make it one of the largest antibiotic producers in Eastern China.
The mission of NeoStem is to accelerate the development of proprietary cellular therapies, with the goal of becoming a global source for the collection, storage, production, therapeutic development, and the transportation of cells for cell-based medicine and regenerative science.
For additional information, visit the company’s website at www.NeoStem.com
Let us hear your thoughts below:
